My name is Mark B. Spiegel and I'm the Managing Member of Stanphyl Capital Management LLC. I can be reached at: mark (at) stanphylcap (dot) com. My Twitter feed is @markbspiegel
Editor for The Biotech Forum (www.biotechforumsa.com), the #2 subscribed to Marketplace investment service offered through SeekingAlpha. Top 5% ranked analyst (TipRanks) 2013 through first half of 2015. Daily contributor for Real Money Pro. Hedge fund manager from 2008 to 2011. Previously technology executive at Fortune 100 firm for a decade. For Free weekly investment reports on small, attractive biotech stocks just register at www.bretjenseninvests.com
Moon Kil Woong is currently a VP at a SME. Previously he was a tech stock consultant, VP of Research at ING, and sell side Director at Crédit Agricole Indosuez. Moon Kil Woong has a Masters in Public Administration from SJSU.
Wall Street Teacher (a pseudonym) worked on Wall Street for several years in the fixed income area and now teaches and writes on financial topics (primarily regulation and markets). Current interests include the psychology of financial markets, the origins of chemistry/physics, synthetic biology, human evolution,siege engines, antique prints, truffles, old cameras, debunking "short and distort" hit pieces, picking RJ Kirk's brain, Battlefield III (we all have our vices) and horology.
Copperfield Research is the pseudonym of a research team focusing on publicly traded equities. As of the publication date of our articles, we may have long or short equity positions in the companies covered. We do not discuss unpublished reports, or provide any advanced warning of future reports to others. Due to the danger of retaliation, our reports are written under a pseudonym. Please read our Disclaimer on the front page of every opinion piece before reading any of the material.
I am currently an undergraduate student majoring in Finance and Computer Science. I plan on writing articles with a focus on growth companies and the TMT sector. I have been investing for four years now primarily in REIT's and Tech companies where I have outperformed respective indices and the S&P500 as a whole.
To view a historical list of all the companies that have been the subject of my articles, please follow the link: https://docs.google.com/spreadsheets/d/170rHmTxaaFpcXyGFWiwYXn8py0g8m67eL10G-LVisxo/edit?usp=sharing
In the spreadsheet, you can have the ability to assess my track record and performance.
I am a Master Engineer I/Scientist working in the Aerospace industry. My 401 K money is mostly in stocks via funds. I trade biotech stocks with my discretionary funds (in my spare time). I do not short, but I will take gains over the short term.
2013 Performance: Weighted average gain per trade: 15%; Best Single Trade: 157% (KERX); Worst Single Trade: -84% (CLSN).
2014 Performance: Weighted average gain per trade: 12.6%; Best Single Trade: 112% (ASPX); Worst Single Trade: -91% (AFFY).
2015 Performance: Weighted average gain per trade: 13.2%; Best Single Trade: 79% (RMTI); Worst Single Trade: -93% (UNIS). If I had closed out all my positions on 12/31/15, my net return since account inception in 2011 would have been -7.2%. Ouch. But I'm planting seeds, right? Time will tell whether they grow into anything.
I am a medical professional that enjoys investing in biotech stocks. I take long positions and may dabble in options. I have a particular interest in biotechs with an ophthalmic (eye) focus as that is where I have developed the greatest expertise over my career and research. I hope over time to share some of my professional insights with those of the Seeking Alpha community in order to help them make more informed investing decisions. I expect to learn a lot from others as well.
I am long the following biotechs at this time: GILD, OPHT, CRMD, ACAD, RLYP, HALO, TGTX, APHB, ZIOP.
I am advising everyone to avoid: OHRP
Brad Lamensdorf, a seasoned money manager and market strategist, is the editor of The Lamensdorf Market Timing Report, a newsletter designed to help investors improve performance via market timing by assessing the environment of the stock market using a variety of technical, fundamental and sentiment-oriented tools from powerful independent research firms. Many investors mechanically enter and depart the market without a true “game plan.” Studies have shown that retail investors, in particular, are very poor market timers, tending to invest at or near market peaks and sell at or near market lows. The newsletter is designed to provide risk parameters for both professional and retail investors around the short-term stock market environment, giving subscribers better insight about when to allocate assets into or out of the equity markets.
Lamensdorf, a frequent guest commentator and analyst on major business networks including CNBC, CNN and Fox Business News, also serves as a Portfolio Manager and Principal of Ranger Alternative Management LP, a sub-advisor to the Advisor Shares Ranger Equity Bear Exchange Traded Fund (NYSE: HDGE). In this role, he conducts top-down technical evaluations of broader market liquidity, sentiment and breadth to help identify short and intermediate-term market trends, manage exposure and mitigate risk. HDGE was launched in 2011 and is the first and sole actively managed, short-only ETF in existence.
Lamensdorf, also has managed investment portfolios for the Hughes family and acted as principal of Tarpon Partners, managing a long/short fund that was up more than 150% gross over six years. Earlier in his career, he was as an equity trader/market strategist for Taylor and Company, the Bass brothers’ trading arm, co-managing a short-only strategy in a derivative format with notional exposure. He also served as the in-house market timing strategist for the entire internal and external network of Bass managers.
Ian Bezek worked for 3 years as an analyst at a New York-based hedge fund. He's currently living in Mexico, pursuing some entrepreneurial opportunities.
Feel free to contact him regarding investments, writing, or speaking opportunities.
I am an independent, self-directed trader with a strong background in accounting. Trading is a hobby I conduct outside of my career as a CPA. I have a technical and fundamental approach towards the equity capital markets and use this knowledge to identify low risk, high-reward trades. Trading is one of my passions and I am continually evolving as a trader as I work towards my goal of developing market intuition.
Disclaimer: I am not an investment advisor and do not provide specific investment advice. I do not receive compensation for any of the articles I submit to Seeking Alpha for publishing. My articles are for informational purposes only and I do not attest to their accuracy or completeness. Please consult your investment advisor before making an investment decision.
Harry S. Dent Jr. studied economics in college in the 1970s, receiving his MBA from Harvard Business School, where he was a Baker Scholar and was elected to the Century Club for leadership excellence. Harry grew to find the study of economics vague and inconclusive and became so disillusioned by the state of his chosen profession that he turned his back on it. Instead, he threw himself into the burgeoning new science of finance which married economic research and market research. Identifying and studying demographic trends, business cycles, consumers’ purchasing power and many other trends empowered Harry to forecast economic and market changes.
The core of his work the “Dent Method” (forecasting long-term economic trends based on the study of and changes in demographic trends) was developed by Harry in the late 1980s.
Since then, he’s spoken to executives, financial advisors and investors around the world. He’s appeared on “Good Morning America,” PBS, CNBC and CNN/Fox News. He’s been featured in Barron’s, Investor’s Business Daily, Entrepreneur, Fortune, Success, U.S. News and World Report, Business Week, The Wall Street Journal, American Demographics and Omni. He is a regular guest on Fox Business’s “America’s Nightly Scorecard.”
A best-selling author, Harry has written numerous successful books over the years, including The Demographic Cliff – How to Survive and Prosper During the Great Deflation of 2014–2019, which details why we’re facing a “great deflation” after five years of stimulus — and what to do about it now. Most recently, Harry published The Sale of a Lifetime: How the Great Bubble Burst of 2017 Can Make You Rich, looking at the upcoming economic crisis and revealing how it could be the single greatest chance to build wealth we’ll ever see, and how we can capitalize on such a unique and historical opportunity.
I'm the guilty conscience of all the world's overconfident stock tip subscription bloggers, financial advisors, hobbyists, and market pundits. In a rare moment of honest self-reflection, I admit that the following popular activities add no long term value compared to index funds:
Paying for stock tip subscriptions.
Obsessing about dividends or dividend streaks.
Scrounging income by selling options.
Forecasting interest rates, commodity prices, and stock market returns.
Paying an advisor 1% of assets under management to create a portfolio of mutual funds.
Following consensus superstitions such as support levels and resistance.
Believing that valuation graphs identify undervalued stocks.
Thinking that beating the S&P 500 for several years predicts future outperformance.
Laboriously building a portfolio that's like an existing no-effort ETF but without the benefit of diversification.
Adam Gefvert is the head researcher for White Diamond Research, a research firm for hedge funds and high net worth individuals. Primarily a short seller, he has saved investors millions of dollars by exposing highly overvalued small cap stocks. He has a 90%+ success rate with his Seeking Alpha short ideas. He specializes in technology, energy, and biotech stocks, because those are the sectors with the greatest valuation inefficiencies.
You can follow Adam on twitter @shiningboy
James has degrees in both Economics and Political Science. He is a small business owner with several years of past political experience and 17 years of active investing.
You can get a 48-72 hour advantage on all his work through Value Investor's Edge as well as exclusive research and analysis by J. Mintzmyer.
I am a retired Registered Nurse interested in biotech and new technology.
I am the Delta Sigmoid (dumb sh__)
I have no idea why people "follow" me, as I know next to nothing, and what I do know is enough to be dangerous to myself and others, I am good at sticking foot in mouth, and sticking up for people, and once in a while I even amuse myself!
It's a good thing I don't manage my own portfolio, I have mad money to play penny stocks, more fun than gambling, but my penny stock picks suck too!
Good luck to all!
Now where's my drink? ;)
I am an independent trader. I have been trading my own money for over 20 years.
I am focused on finding growth stocks that are priced like value stocks or stocks that are misunderstood or under followed. Generally, I buy stocks where I feel like my chances of losing money are low, but still offer the possibility of large gains. This almost always leads me to small and microcap cap stocks.
I joined Seeking Alpha to share some of my ideas with others. I hope they are profitable.
Please do your own due diligence and do not blindly buy stocks on Seeking Alpha articles alone (including mine).
Brad Thomas is a research analyst and he currently writes weekly for Forbes and Seeking Alpha where he maintains research on many publicly-listed REITs. In addition, Thomas is the Senior Analyst at iREIT Forbes and Editor of the Forbes Real Estate Investor, a monthly subscription-based newsletter.
Thomas has also been featured in Forbes Magazine, Kiplinger’s, US News & World Report, Money, NPR, Institutional Investor, GlobeStreet, and Fox Business. He was the #1 contributing analyst on Seeking Alpha in 2014 (as ranked by TipRanks) and he is currently writing a book on the legendary investor Donald Trump.
Thomas has co-authored a book (The Intelligent REIT Investor) that is available on Amazon.
Thomas received a Bachelor of Science degree in Business/Economics from Presbyterian College where he played basketball. He resides in South Carolina with his wife and kids.